nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—KIT—thymus cancer	0.644	1	CbGaD
Nilotinib—CA3—pericardium—thymus cancer	0.00544	0.0418	CbGeAlD
Nilotinib—EPHA2—pulmonary artery—thymus cancer	0.00535	0.0411	CbGeAlD
Nilotinib—Ponatinib—KIT—thymus cancer	0.00396	0.619	CrCbGaD
Nilotinib—Haemorrhoids—Octreotide—thymus cancer	0.00279	0.0236	CcSEcCtD
Nilotinib—Haematoma—Octreotide—thymus cancer	0.00261	0.0221	CcSEcCtD
Nilotinib—Hypothyroidism—Octreotide—thymus cancer	0.00255	0.0216	CcSEcCtD
Nilotinib—Imatinib—KIT—thymus cancer	0.00244	0.381	CrCbGaD
Nilotinib—Blood creatine phosphokinase increased—Octreotide—thymus cancer	0.00238	0.0202	CcSEcCtD
Nilotinib—Cholestasis—Octreotide—thymus cancer	0.00216	0.0183	CcSEcCtD
Nilotinib—Petechiae—Octreotide—thymus cancer	0.00199	0.0169	CcSEcCtD
Nilotinib—Endocrine disorder—Octreotide—thymus cancer	0.00198	0.0167	CcSEcCtD
Nilotinib—Breast pain—Octreotide—thymus cancer	0.00188	0.0159	CcSEcCtD
Nilotinib—Contusion—Octreotide—thymus cancer	0.00188	0.0159	CcSEcCtD
Nilotinib—MAPK8—neck—thymus cancer	0.00187	0.0144	CbGeAlD
Nilotinib—FRK—hematopoietic system—thymus cancer	0.00183	0.014	CbGeAlD
Nilotinib—Rectal haemorrhage—Octreotide—thymus cancer	0.00182	0.0154	CcSEcCtD
Nilotinib—Hyperbilirubinaemia—Octreotide—thymus cancer	0.0018	0.0153	CcSEcCtD
Nilotinib—Oropharyngeal pain—Octreotide—thymus cancer	0.0018	0.0153	CcSEcCtD
Nilotinib—Herpes simplex—Octreotide—thymus cancer	0.00178	0.0151	CcSEcCtD
Nilotinib—BLK—hematopoietic system—thymus cancer	0.00176	0.0135	CbGeAlD
Nilotinib—EPHB2—hematopoietic system—thymus cancer	0.00174	0.0134	CbGeAlD
Nilotinib—Hearing impaired—Octreotide—thymus cancer	0.00172	0.0146	CcSEcCtD
Nilotinib—Phosphatase alkaline increased—Octreotide—thymus cancer	0.00164	0.0139	CcSEcCtD
Nilotinib—Hyperkalaemia—Octreotide—thymus cancer	0.00161	0.0136	CcSEcCtD
Nilotinib—Influenza like illness—Octreotide—thymus cancer	0.00159	0.0135	CcSEcCtD
Nilotinib—Wheezing—Octreotide—thymus cancer	0.00159	0.0135	CcSEcCtD
Nilotinib—Candida infection—Octreotide—thymus cancer	0.00157	0.0132	CcSEcCtD
Nilotinib—Mouth ulceration—Octreotide—thymus cancer	0.00148	0.0125	CcSEcCtD
Nilotinib—Gynaecomastia—Octreotide—thymus cancer	0.00147	0.0124	CcSEcCtD
Nilotinib—MAPK8—hematopoietic system—thymus cancer	0.00139	0.0107	CbGeAlD
Nilotinib—Blood alkaline phosphatase increased—Octreotide—thymus cancer	0.00137	0.0116	CcSEcCtD
Nilotinib—Diabetes mellitus—Octreotide—thymus cancer	0.00137	0.0116	CcSEcCtD
Nilotinib—Gastroenteritis—Octreotide—thymus cancer	0.00134	0.0114	CcSEcCtD
Nilotinib—Deafness—Octreotide—thymus cancer	0.00133	0.0113	CcSEcCtD
Nilotinib—FRK—lymphoid tissue—thymus cancer	0.00129	0.00988	CbGeAlD
Nilotinib—LYN—hematopoietic system—thymus cancer	0.00129	0.00988	CbGeAlD
Nilotinib—MAPK8—epithelium—thymus cancer	0.00127	0.00979	CbGeAlD
Nilotinib—Amnesia—Octreotide—thymus cancer	0.00127	0.0107	CcSEcCtD
Nilotinib—MAP4K1—hematopoietic system—thymus cancer	0.00127	0.00973	CbGeAlD
Nilotinib—BLK—lymphoid tissue—thymus cancer	0.00124	0.00954	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—thymus cancer	0.00123	0.00943	CbGeAlD
Nilotinib—Arthritis—Octreotide—thymus cancer	0.00122	0.0104	CcSEcCtD
Nilotinib—Hypoglycaemia—Octreotide—thymus cancer	0.00122	0.0103	CcSEcCtD
Nilotinib—TIE1—hematopoietic system—thymus cancer	0.00121	0.00928	CbGeAlD
Nilotinib—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00119	0.0101	CcSEcCtD
Nilotinib—Pain in extremity—Octreotide—thymus cancer	0.00119	0.0101	CcSEcCtD
Nilotinib—MAPK14—neck—thymus cancer	0.00119	0.00914	CbGeAlD
Nilotinib—CDC42BPB—cardiac atrium—thymus cancer	0.00117	0.00899	CbGeAlD
Nilotinib—CDC42BPB—pituitary gland—thymus cancer	0.00114	0.00878	CbGeAlD
Nilotinib—Dehydration—Octreotide—thymus cancer	0.00111	0.00936	CcSEcCtD
Nilotinib—TIE1—epithelium—thymus cancer	0.0011	0.00849	CbGeAlD
Nilotinib—Dry skin—Octreotide—thymus cancer	0.00109	0.00923	CcSEcCtD
Nilotinib—Abdominal pain upper—Octreotide—thymus cancer	0.00109	0.0092	CcSEcCtD
Nilotinib—Nasopharyngitis—Octreotide—thymus cancer	0.00106	0.009	CcSEcCtD
Nilotinib—HCK—hematopoietic system—thymus cancer	0.00106	0.00811	CbGeAlD
Nilotinib—Gastritis—Octreotide—thymus cancer	0.00105	0.00891	CcSEcCtD
Nilotinib—Muscular weakness—Octreotide—thymus cancer	0.00105	0.00888	CcSEcCtD
Nilotinib—Abdominal distension—Octreotide—thymus cancer	0.00104	0.00876	CcSEcCtD
Nilotinib—MAPK8—pituitary gland—thymus cancer	0.00103	0.00794	CbGeAlD
Nilotinib—Influenza—Octreotide—thymus cancer	0.00103	0.0087	CcSEcCtD
Nilotinib—Pancreatitis—Octreotide—thymus cancer	0.00101	0.00853	CcSEcCtD
Nilotinib—MAPK11—thyroid gland—thymus cancer	0.000993	0.00763	CbGeAlD
Nilotinib—Bronchitis—Octreotide—thymus cancer	0.000989	0.00837	CcSEcCtD
Nilotinib—Abdominal discomfort—Octreotide—thymus cancer	0.000986	0.00834	CcSEcCtD
Nilotinib—CDC42BPB—thyroid gland—thymus cancer	0.000985	0.00757	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—thymus cancer	0.000981	0.00754	CbGeAlD
Nilotinib—Dysuria—Octreotide—thymus cancer	0.000962	0.00814	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Octreotide—thymus cancer	0.000956	0.00809	CcSEcCtD
Nilotinib—Pollakiuria—Octreotide—thymus cancer	0.00095	0.00804	CcSEcCtD
Nilotinib—Weight increased—Octreotide—thymus cancer	0.000936	0.00792	CcSEcCtD
Nilotinib—EPHA3—thyroid gland—thymus cancer	0.000934	0.00718	CbGeAlD
Nilotinib—Weight decreased—Octreotide—thymus cancer	0.000931	0.00787	CcSEcCtD
Nilotinib—Hyperglycaemia—Octreotide—thymus cancer	0.000928	0.00785	CcSEcCtD
Nilotinib—Pneumonia—Octreotide—thymus cancer	0.000923	0.0078	CcSEcCtD
Nilotinib—TIE1—cardiac atrium—thymus cancer	0.000917	0.00705	CbGeAlD
Nilotinib—LYN—lymphoid tissue—thymus cancer	0.000905	0.00696	CbGeAlD
Nilotinib—Neuropathy peripheral—Octreotide—thymus cancer	0.000899	0.00761	CcSEcCtD
Nilotinib—CDC42BPB—lung—thymus cancer	0.000895	0.00688	CbGeAlD
Nilotinib—Jaundice—Octreotide—thymus cancer	0.000894	0.00756	CcSEcCtD
Nilotinib—MAPK8—bone marrow—thymus cancer	0.000893	0.00686	CbGeAlD
Nilotinib—Urinary tract infection—Octreotide—thymus cancer	0.000892	0.00754	CcSEcCtD
Nilotinib—Conjunctivitis—Octreotide—thymus cancer	0.000892	0.00754	CcSEcCtD
Nilotinib—MAP4K1—lymphoid tissue—thymus cancer	0.000891	0.00685	CbGeAlD
Nilotinib—MAPK8—thyroid gland—thymus cancer	0.000891	0.00685	CbGeAlD
Nilotinib—MAPK14—hematopoietic system—thymus cancer	0.000885	0.0068	CbGeAlD
Nilotinib—FGR—hematopoietic system—thymus cancer	0.000881	0.00677	CbGeAlD
Nilotinib—Haematuria—Octreotide—thymus cancer	0.000875	0.0074	CcSEcCtD
Nilotinib—Hepatobiliary disease—Octreotide—thymus cancer	0.000867	0.00734	CcSEcCtD
Nilotinib—Epistaxis—Octreotide—thymus cancer	0.000865	0.00732	CcSEcCtD
Nilotinib—BRAF—pituitary gland—thymus cancer	0.000859	0.0066	CbGeAlD
Nilotinib—EPHA3—lung—thymus cancer	0.000848	0.00652	CbGeAlD
Nilotinib—EPHB4—hematopoietic system—thymus cancer	0.000839	0.00645	CbGeAlD
Nilotinib—Bradycardia—Octreotide—thymus cancer	0.000838	0.00709	CcSEcCtD
Nilotinib—Rhinitis—Octreotide—thymus cancer	0.000825	0.00698	CcSEcCtD
Nilotinib—Hepatitis—Octreotide—thymus cancer	0.000823	0.00697	CcSEcCtD
Nilotinib—EPHA2—hematopoietic system—thymus cancer	0.000823	0.00632	CbGeAlD
Nilotinib—Hypoaesthesia—Octreotide—thymus cancer	0.000819	0.00693	CcSEcCtD
Nilotinib—Pharyngitis—Octreotide—thymus cancer	0.000817	0.00691	CcSEcCtD
Nilotinib—MAP4K1—bone marrow—thymus cancer	0.000812	0.00624	CbGeAlD
Nilotinib—Oedema peripheral—Octreotide—thymus cancer	0.000811	0.00686	CcSEcCtD
Nilotinib—MAP4K1—thyroid gland—thymus cancer	0.00081	0.00622	CbGeAlD
Nilotinib—MAPK8—lung—thymus cancer	0.000809	0.00622	CbGeAlD
Nilotinib—MAPK14—epithelium—thymus cancer	0.000809	0.00622	CbGeAlD
Nilotinib—TEK—hematopoietic system—thymus cancer	0.000803	0.00617	CbGeAlD
Nilotinib—Visual impairment—Octreotide—thymus cancer	0.000794	0.00671	CcSEcCtD
Nilotinib—HCK—pituitary gland—thymus cancer	0.000783	0.00602	CbGeAlD
Nilotinib—KIT—neck—thymus cancer	0.000781	0.006	CbGeAlD
Nilotinib—ABL2—pituitary gland—thymus cancer	0.000778	0.00598	CbGeAlD
Nilotinib—TIE1—thyroid gland—thymus cancer	0.000772	0.00594	CbGeAlD
Nilotinib—Tinnitus—Octreotide—thymus cancer	0.000768	0.00649	CcSEcCtD
Nilotinib—EPHB4—epithelium—thymus cancer	0.000767	0.00589	CbGeAlD
Nilotinib—Flushing—Octreotide—thymus cancer	0.000764	0.00646	CcSEcCtD
Nilotinib—Cardiac disorder—Octreotide—thymus cancer	0.000764	0.00646	CcSEcCtD
Nilotinib—PDGFRB—neck—thymus cancer	0.000763	0.00586	CbGeAlD
Nilotinib—EPHA2—epithelium—thymus cancer	0.000752	0.00578	CbGeAlD
Nilotinib—Immune system disorder—Octreotide—thymus cancer	0.000744	0.00629	CcSEcCtD
Nilotinib—HCK—lymphoid tissue—thymus cancer	0.000743	0.00571	CbGeAlD
Nilotinib—BRAF—bone marrow—thymus cancer	0.000742	0.00571	CbGeAlD
Nilotinib—BRAF—thyroid gland—thymus cancer	0.000741	0.00569	CbGeAlD
Nilotinib—Arrhythmia—Octreotide—thymus cancer	0.000736	0.00622	CcSEcCtD
Nilotinib—MAP4K1—lung—thymus cancer	0.000735	0.00565	CbGeAlD
Nilotinib—TEK—epithelium—thymus cancer	0.000734	0.00564	CbGeAlD
Nilotinib—EPHA4—cardiac atrium—thymus cancer	0.000729	0.0056	CbGeAlD
Nilotinib—Alopecia—Octreotide—thymus cancer	0.000728	0.00616	CcSEcCtD
Nilotinib—PDGFRA—hematopoietic system—thymus cancer	0.000727	0.00559	CbGeAlD
Nilotinib—Mental disorder—Octreotide—thymus cancer	0.000721	0.0061	CcSEcCtD
Nilotinib—CA3—cardiac atrium—thymus cancer	0.00072	0.00553	CbGeAlD
Nilotinib—Malnutrition—Octreotide—thymus cancer	0.000717	0.00606	CcSEcCtD
Nilotinib—Erythema—Octreotide—thymus cancer	0.000717	0.00606	CcSEcCtD
Nilotinib—EPHA4—pituitary gland—thymus cancer	0.000712	0.00547	CbGeAlD
Nilotinib—Flatulence—Octreotide—thymus cancer	0.000706	0.00598	CcSEcCtD
Nilotinib—CA3—pituitary gland—thymus cancer	0.000703	0.0054	CbGeAlD
Nilotinib—TIE1—lung—thymus cancer	0.000702	0.00539	CbGeAlD
Nilotinib—BLK—lymph node—thymus cancer	0.0007	0.00538	CbGeAlD
Nilotinib—UGT1A1—hematopoietic system—thymus cancer	0.000694	0.00533	CbGeAlD
Nilotinib—Back pain—Octreotide—thymus cancer	0.000693	0.00587	CcSEcCtD
Nilotinib—Muscle spasms—Octreotide—thymus cancer	0.000689	0.00583	CcSEcCtD
Nilotinib—HCK—bone marrow—thymus cancer	0.000677	0.0052	CbGeAlD
Nilotinib—Vision blurred—Octreotide—thymus cancer	0.000676	0.00571	CcSEcCtD
Nilotinib—HCK—thyroid gland—thymus cancer	0.000675	0.00519	CbGeAlD
Nilotinib—BRAF—lung—thymus cancer	0.000673	0.00517	CbGeAlD
Nilotinib—Tremor—Octreotide—thymus cancer	0.000672	0.00568	CcSEcCtD
Nilotinib—ABL2—thyroid gland—thymus cancer	0.000671	0.00516	CbGeAlD
Nilotinib—EPHB3—lung—thymus cancer	0.000667	0.00513	CbGeAlD
Nilotinib—Ill-defined disorder—Octreotide—thymus cancer	0.000665	0.00563	CcSEcCtD
Nilotinib—Anaemia—Octreotide—thymus cancer	0.000663	0.0056	CcSEcCtD
Nilotinib—MAPK14—pituitary gland—thymus cancer	0.000656	0.00504	CbGeAlD
Nilotinib—FGR—pituitary gland—thymus cancer	0.000654	0.00502	CbGeAlD
Nilotinib—CA14—cardiac atrium—thymus cancer	0.000654	0.00502	CbGeAlD
Nilotinib—Malaise—Octreotide—thymus cancer	0.000646	0.00547	CcSEcCtD
Nilotinib—Vertigo—Octreotide—thymus cancer	0.000644	0.00545	CcSEcCtD
Nilotinib—Syncope—Octreotide—thymus cancer	0.000643	0.00544	CcSEcCtD
Nilotinib—CSF1R—hematopoietic system—thymus cancer	0.00064	0.00492	CbGeAlD
Nilotinib—EPHB4—cardiac atrium—thymus cancer	0.000637	0.00489	CbGeAlD
Nilotinib—Palpitations—Octreotide—thymus cancer	0.000633	0.00536	CcSEcCtD
Nilotinib—Loss of consciousness—Octreotide—thymus cancer	0.00063	0.00533	CcSEcCtD
Nilotinib—Cough—Octreotide—thymus cancer	0.000625	0.00529	CcSEcCtD
Nilotinib—EPHA2—cardiac atrium—thymus cancer	0.000625	0.0048	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—thymus cancer	0.000623	0.00479	CbGeAlD
Nilotinib—EPHB4—pituitary gland—thymus cancer	0.000622	0.00478	CbGeAlD
Nilotinib—FGR—lymphoid tissue—thymus cancer	0.00062	0.00477	CbGeAlD
Nilotinib—Hypertension—Octreotide—thymus cancer	0.000619	0.00524	CcSEcCtD
Nilotinib—MAPK11—lymph node—thymus cancer	0.000617	0.00474	CbGeAlD
Nilotinib—EPHA4—thyroid gland—thymus cancer	0.000614	0.00472	CbGeAlD
Nilotinib—HCK—lung—thymus cancer	0.000613	0.00471	CbGeAlD
Nilotinib—CDC42BPB—lymph node—thymus cancer	0.000612	0.0047	CbGeAlD
Nilotinib—EPHA2—pituitary gland—thymus cancer	0.00061	0.00469	CbGeAlD
Nilotinib—Myalgia—Octreotide—thymus cancer	0.00061	0.00516	CcSEcCtD
Nilotinib—Arthralgia—Octreotide—thymus cancer	0.00061	0.00516	CcSEcCtD
Nilotinib—Chest pain—Octreotide—thymus cancer	0.00061	0.00516	CcSEcCtD
Nilotinib—TEK—cardiac atrium—thymus cancer	0.00061	0.00468	CbGeAlD
Nilotinib—ABL2—lung—thymus cancer	0.000609	0.00468	CbGeAlD
Nilotinib—Anxiety—Octreotide—thymus cancer	0.000608	0.00514	CcSEcCtD
Nilotinib—CA3—bone marrow—thymus cancer	0.000608	0.00467	CbGeAlD
Nilotinib—CA3—thyroid gland—thymus cancer	0.000606	0.00466	CbGeAlD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.000606	0.00513	CcSEcCtD
Nilotinib—Discomfort—Octreotide—thymus cancer	0.000603	0.0051	CcSEcCtD
Nilotinib—Dry mouth—Octreotide—thymus cancer	0.000597	0.00505	CcSEcCtD
Nilotinib—TEK—pituitary gland—thymus cancer	0.000595	0.00458	CbGeAlD
Nilotinib—Oedema—Octreotide—thymus cancer	0.000585	0.00495	CcSEcCtD
Nilotinib—EPHB6—cardiac atrium—thymus cancer	0.000582	0.00448	CbGeAlD
Nilotinib—KIT—hematopoietic system—thymus cancer	0.000581	0.00447	CbGeAlD
Nilotinib—Infection—Octreotide—thymus cancer	0.000581	0.00492	CcSEcCtD
Nilotinib—EPHA3—lymph node—thymus cancer	0.00058	0.00446	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—thymus cancer	0.000579	0.00445	CbGeAlD
Nilotinib—Shock—Octreotide—thymus cancer	0.000576	0.00487	CcSEcCtD
Nilotinib—Nervous system disorder—Octreotide—thymus cancer	0.000574	0.00485	CcSEcCtD
Nilotinib—Thrombocytopenia—Octreotide—thymus cancer	0.000573	0.00485	CcSEcCtD
Nilotinib—Tachycardia—Octreotide—thymus cancer	0.000571	0.00483	CcSEcCtD
Nilotinib—EPHB6—pituitary gland—thymus cancer	0.000569	0.00437	CbGeAlD
Nilotinib—Skin disorder—Octreotide—thymus cancer	0.000568	0.00481	CcSEcCtD
Nilotinib—PDGFRB—hematopoietic system—thymus cancer	0.000568	0.00436	CbGeAlD
Nilotinib—MAPK14—bone marrow—thymus cancer	0.000567	0.00436	CbGeAlD
Nilotinib—MAPK14—thyroid gland—thymus cancer	0.000566	0.00435	CbGeAlD
Nilotinib—Hyperhidrosis—Octreotide—thymus cancer	0.000566	0.00478	CcSEcCtD
Nilotinib—TEK—lymphoid tissue—thymus cancer	0.000565	0.00434	CbGeAlD
Nilotinib—LCK—bone marrow—thymus cancer	0.000565	0.00434	CbGeAlD
Nilotinib—FGR—bone marrow—thymus cancer	0.000565	0.00434	CbGeAlD
Nilotinib—LCK—thyroid gland—thymus cancer	0.000563	0.00433	CbGeAlD
Nilotinib—FGR—thyroid gland—thymus cancer	0.000563	0.00433	CbGeAlD
Nilotinib—CA4—neck—thymus cancer	0.000558	0.00429	CbGeAlD
Nilotinib—Anorexia—Octreotide—thymus cancer	0.000558	0.00472	CcSEcCtD
Nilotinib—EPHA4—lung—thymus cancer	0.000557	0.00428	CbGeAlD
Nilotinib—MAPK8—lymph node—thymus cancer	0.000553	0.00425	CbGeAlD
Nilotinib—CA3—lung—thymus cancer	0.00055	0.00423	CbGeAlD
Nilotinib—EPHB4—bone marrow—thymus cancer	0.000538	0.00413	CbGeAlD
Nilotinib—EPHB4—thyroid gland—thymus cancer	0.000536	0.00412	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Octreotide—thymus cancer	0.000533	0.00451	CcSEcCtD
Nilotinib—CA1—hematopoietic system—thymus cancer	0.000532	0.00409	CbGeAlD
Nilotinib—KIT—epithelium—thymus cancer	0.000531	0.00408	CbGeAlD
Nilotinib—Insomnia—Octreotide—thymus cancer	0.000529	0.00448	CcSEcCtD
Nilotinib—EPHA2—thyroid gland—thymus cancer	0.000526	0.00404	CbGeAlD
Nilotinib—Paraesthesia—Octreotide—thymus cancer	0.000525	0.00444	CcSEcCtD
Nilotinib—Dyspnoea—Octreotide—thymus cancer	0.000522	0.00441	CcSEcCtD
Nilotinib—PDGFRB—epithelium—thymus cancer	0.000519	0.00399	CbGeAlD
Nilotinib—Dyspepsia—Octreotide—thymus cancer	0.000515	0.00436	CcSEcCtD
Nilotinib—MAPK14—lung—thymus cancer	0.000514	0.00395	CbGeAlD
Nilotinib—TEK—thyroid gland—thymus cancer	0.000513	0.00394	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—thymus cancer	0.000512	0.00393	CbGeAlD
Nilotinib—FGR—lung—thymus cancer	0.000512	0.00393	CbGeAlD
Nilotinib—LCK—lung—thymus cancer	0.000512	0.00393	CbGeAlD
Nilotinib—Decreased appetite—Octreotide—thymus cancer	0.000509	0.0043	CcSEcCtD
Nilotinib—ABL1—hematopoietic system—thymus cancer	0.000506	0.00389	CbGeAlD
Nilotinib—Gastrointestinal disorder—Octreotide—thymus cancer	0.000505	0.00427	CcSEcCtD
Nilotinib—Fatigue—Octreotide—thymus cancer	0.000504	0.00427	CcSEcCtD
Nilotinib—MAP4K1—lymph node—thymus cancer	0.000503	0.00387	CbGeAlD
Nilotinib—Pain—Octreotide—thymus cancer	0.0005	0.00423	CcSEcCtD
Nilotinib—Constipation—Octreotide—thymus cancer	0.0005	0.00423	CcSEcCtD
Nilotinib—MAP2K5—cardiac atrium—thymus cancer	0.000498	0.00383	CbGeAlD
Nilotinib—EPHB6—thyroid gland—thymus cancer	0.000491	0.00377	CbGeAlD
Nilotinib—EPHB4—lung—thymus cancer	0.000487	0.00374	CbGeAlD
Nilotinib—MAP2K5—pituitary gland—thymus cancer	0.000487	0.00374	CbGeAlD
Nilotinib—CSF1R—cardiac atrium—thymus cancer	0.000486	0.00374	CbGeAlD
Nilotinib—Feeling abnormal—Octreotide—thymus cancer	0.000482	0.00408	CcSEcCtD
Nilotinib—TIE1—lymph node—thymus cancer	0.00048	0.00369	CbGeAlD
Nilotinib—Gastrointestinal pain—Octreotide—thymus cancer	0.000478	0.00405	CcSEcCtD
Nilotinib—EPHA2—lung—thymus cancer	0.000478	0.00367	CbGeAlD
Nilotinib—CSF1R—pituitary gland—thymus cancer	0.000475	0.00365	CbGeAlD
Nilotinib—TEK—lung—thymus cancer	0.000466	0.00358	CbGeAlD
Nilotinib—PDGFRA—thyroid gland—thymus cancer	0.000465	0.00357	CbGeAlD
Nilotinib—Urticaria—Octreotide—thymus cancer	0.000465	0.00393	CcSEcCtD
Nilotinib—CA2—neck—thymus cancer	0.000463	0.00356	CbGeAlD
Nilotinib—Body temperature increased—Octreotide—thymus cancer	0.000462	0.00391	CcSEcCtD
Nilotinib—Abdominal pain—Octreotide—thymus cancer	0.000462	0.00391	CcSEcCtD
Nilotinib—BRAF—lymph node—thymus cancer	0.00046	0.00354	CbGeAlD
Nilotinib—EPHB3—lymph node—thymus cancer	0.000456	0.00351	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—thymus cancer	0.000451	0.00346	CbGeAlD
Nilotinib—EPHB6—lung—thymus cancer	0.000446	0.00342	CbGeAlD
Nilotinib—KIT—pituitary gland—thymus cancer	0.000431	0.00331	CbGeAlD
Nilotinib—PDGFRB—cardiac atrium—thymus cancer	0.000431	0.00331	CbGeAlD
Nilotinib—Hypersensitivity—Octreotide—thymus cancer	0.000431	0.00365	CcSEcCtD
Nilotinib—PDGFRA—lung—thymus cancer	0.000422	0.00325	CbGeAlD
Nilotinib—PDGFRB—pituitary gland—thymus cancer	0.000421	0.00324	CbGeAlD
Nilotinib—Asthenia—Octreotide—thymus cancer	0.00042	0.00355	CcSEcCtD
Nilotinib—MAP2K5—thyroid gland—thymus cancer	0.000419	0.00322	CbGeAlD
Nilotinib—HCK—lymph node—thymus cancer	0.000419	0.00322	CbGeAlD
Nilotinib—ABL2—lymph node—thymus cancer	0.000417	0.0032	CbGeAlD
Nilotinib—Pruritus—Octreotide—thymus cancer	0.000414	0.0035	CcSEcCtD
Nilotinib—CSF1R—bone marrow—thymus cancer	0.00041	0.00315	CbGeAlD
Nilotinib—CSF1R—thyroid gland—thymus cancer	0.000409	0.00315	CbGeAlD
Nilotinib—KIT—lymphoid tissue—thymus cancer	0.000409	0.00315	CbGeAlD
Nilotinib—Diarrhoea—Octreotide—thymus cancer	0.0004	0.00339	CcSEcCtD
Nilotinib—PDGFRB—lymphoid tissue—thymus cancer	0.0004	0.00307	CbGeAlD
Nilotinib—CA12—lung—thymus cancer	0.00039	0.003	CbGeAlD
Nilotinib—Dizziness—Octreotide—thymus cancer	0.000387	0.00327	CcSEcCtD
Nilotinib—ABL1—cardiac atrium—thymus cancer	0.000384	0.00295	CbGeAlD
Nilotinib—EPHA4—lymph node—thymus cancer	0.000381	0.00293	CbGeAlD
Nilotinib—MAP2K5—lung—thymus cancer	0.000381	0.00293	CbGeAlD
Nilotinib—CA3—lymph node—thymus cancer	0.000377	0.00289	CbGeAlD
Nilotinib—ABL1—pituitary gland—thymus cancer	0.000375	0.00289	CbGeAlD
Nilotinib—CA1—lymphoid tissue—thymus cancer	0.000374	0.00288	CbGeAlD
Nilotinib—KIT—bone marrow—thymus cancer	0.000373	0.00286	CbGeAlD
Nilotinib—Vomiting—Octreotide—thymus cancer	0.000372	0.00315	CcSEcCtD
Nilotinib—CSF1R—lung—thymus cancer	0.000372	0.00286	CbGeAlD
Nilotinib—KIT—thyroid gland—thymus cancer	0.000372	0.00286	CbGeAlD
Nilotinib—Rash—Octreotide—thymus cancer	0.000369	0.00312	CcSEcCtD
Nilotinib—Dermatitis—Octreotide—thymus cancer	0.000369	0.00312	CcSEcCtD
Nilotinib—Headache—Octreotide—thymus cancer	0.000366	0.0031	CcSEcCtD
Nilotinib—PDGFRB—bone marrow—thymus cancer	0.000364	0.0028	CbGeAlD
Nilotinib—PDGFRB—thyroid gland—thymus cancer	0.000363	0.00279	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—thymus cancer	0.000356	0.00274	CbGeAlD
Nilotinib—MAPK14—lymph node—thymus cancer	0.000351	0.0027	CbGeAlD
Nilotinib—LCK—lymph node—thymus cancer	0.00035	0.00269	CbGeAlD
Nilotinib—FGR—lymph node—thymus cancer	0.00035	0.00269	CbGeAlD
Nilotinib—Nausea—Octreotide—thymus cancer	0.000347	0.00294	CcSEcCtD
Nilotinib—CA2—hematopoietic system—thymus cancer	0.000345	0.00265	CbGeAlD
Nilotinib—CA1—bone marrow—thymus cancer	0.000341	0.00262	CbGeAlD
Nilotinib—KIT—lung—thymus cancer	0.000338	0.0026	CbGeAlD
Nilotinib—EPHB4—lymph node—thymus cancer	0.000333	0.00256	CbGeAlD
Nilotinib—PDGFRB—lung—thymus cancer	0.00033	0.00253	CbGeAlD
Nilotinib—CYP2C8—hematopoietic system—thymus cancer	0.000328	0.00252	CbGeAlD
Nilotinib—EPHA2—lymph node—thymus cancer	0.000327	0.00251	CbGeAlD
Nilotinib—ABL1—bone marrow—thymus cancer	0.000324	0.00249	CbGeAlD
Nilotinib—ABL1—thyroid gland—thymus cancer	0.000324	0.00249	CbGeAlD
Nilotinib—TEK—lymph node—thymus cancer	0.000319	0.00245	CbGeAlD
Nilotinib—CA4—cardiac atrium—thymus cancer	0.000316	0.00243	CbGeAlD
Nilotinib—CA2—epithelium—thymus cancer	0.000315	0.00242	CbGeAlD
Nilotinib—CA1—lung—thymus cancer	0.000309	0.00237	CbGeAlD
Nilotinib—CA4—pituitary gland—thymus cancer	0.000308	0.00237	CbGeAlD
Nilotinib—EPHB6—lymph node—thymus cancer	0.000305	0.00234	CbGeAlD
Nilotinib—CYP2B6—hematopoietic system—thymus cancer	0.000294	0.00226	CbGeAlD
Nilotinib—ABL1—lung—thymus cancer	0.000294	0.00226	CbGeAlD
Nilotinib—CYP2C9—hematopoietic system—thymus cancer	0.000292	0.00224	CbGeAlD
Nilotinib—PDGFRA—lymph node—thymus cancer	0.000289	0.00222	CbGeAlD
Nilotinib—CA4—bone marrow—thymus cancer	0.000266	0.00205	CbGeAlD
Nilotinib—CA4—thyroid gland—thymus cancer	0.000266	0.00204	CbGeAlD
Nilotinib—CA2—cardiac atrium—thymus cancer	0.000262	0.00201	CbGeAlD
Nilotinib—MAP2K5—lymph node—thymus cancer	0.000261	0.002	CbGeAlD
Nilotinib—CA2—pituitary gland—thymus cancer	0.000256	0.00196	CbGeAlD
Nilotinib—CSF1R—lymph node—thymus cancer	0.000254	0.00195	CbGeAlD
Nilotinib—CYP2C8—pituitary gland—thymus cancer	0.000243	0.00187	CbGeAlD
Nilotinib—CA2—lymphoid tissue—thymus cancer	0.000243	0.00186	CbGeAlD
Nilotinib—CA4—lung—thymus cancer	0.000241	0.00186	CbGeAlD
Nilotinib—ABCG2—pituitary gland—thymus cancer	0.000237	0.00182	CbGeAlD
Nilotinib—KIT—lymph node—thymus cancer	0.000231	0.00177	CbGeAlD
Nilotinib—PDGFRB—lymph node—thymus cancer	0.000226	0.00173	CbGeAlD
Nilotinib—CYP3A4—hematopoietic system—thymus cancer	0.000222	0.00171	CbGeAlD
Nilotinib—CA2—bone marrow—thymus cancer	0.000221	0.0017	CbGeAlD
Nilotinib—CA2—thyroid gland—thymus cancer	0.00022	0.00169	CbGeAlD
Nilotinib—CYP2D6—hematopoietic system—thymus cancer	0.000219	0.00168	CbGeAlD
Nilotinib—CA1—lymph node—thymus cancer	0.000211	0.00162	CbGeAlD
Nilotinib—CYP2B6—lymphoid tissue—thymus cancer	0.000207	0.00159	CbGeAlD
Nilotinib—ABCG2—bone marrow—thymus cancer	0.000205	0.00157	CbGeAlD
Nilotinib—ABCG2—thyroid gland—thymus cancer	0.000204	0.00157	CbGeAlD
Nilotinib—ABL1—lymph node—thymus cancer	0.000201	0.00155	CbGeAlD
Nilotinib—CA2—lung—thymus cancer	0.0002	0.00154	CbGeAlD
Nilotinib—ABCG2—lung—thymus cancer	0.000185	0.00142	CbGeAlD
Nilotinib—CYP2B6—lung—thymus cancer	0.000171	0.00131	CbGeAlD
Nilotinib—CA4—lymph node—thymus cancer	0.000165	0.00127	CbGeAlD
Nilotinib—ABCB1—hematopoietic system—thymus cancer	0.000157	0.00121	CbGeAlD
Nilotinib—ABCB1—epithelium—thymus cancer	0.000144	0.00111	CbGeAlD
Nilotinib—CA2—lymph node—thymus cancer	0.000137	0.00105	CbGeAlD
Nilotinib—ABCG2—lymph node—thymus cancer	0.000127	0.000974	CbGeAlD
Nilotinib—ABCB1—pituitary gland—thymus cancer	0.000117	0.000897	CbGeAlD
Nilotinib—ABCB1—lymphoid tissue—thymus cancer	0.000111	0.000852	CbGeAlD
Nilotinib—ABCB1—bone marrow—thymus cancer	0.000101	0.000775	CbGeAlD
Nilotinib—ABCB1—thyroid gland—thymus cancer	0.000101	0.000773	CbGeAlD
Nilotinib—ABCB1—lung—thymus cancer	9.14e-05	0.000702	CbGeAlD
Nilotinib—ABCB1—lymph node—thymus cancer	6.25e-05	0.00048	CbGeAlD
Nilotinib—PDGFRB—MAPK Signaling Pathway—AKT1—thymus cancer	3.41e-05	0.000337	CbGpPWpGaD
Nilotinib—KIT—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	3.4e-05	0.000336	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	3.38e-05	0.000334	CbGpPWpGaD
Nilotinib—PDGFRA—B Cell Activation—AKT1—thymus cancer	3.36e-05	0.000332	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD8A—thymus cancer	3.36e-05	0.000332	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IL2—thymus cancer	3.36e-05	0.000332	CbGpPWpGaD
Nilotinib—EPHA6—Developmental Biology—AKT1—thymus cancer	3.35e-05	0.000331	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—KIT—thymus cancer	3.33e-05	0.000329	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—CD4—thymus cancer	3.31e-05	0.000327	CbGpPWpGaD
Nilotinib—MAPK14—Insulin Signaling—AKT1—thymus cancer	3.29e-05	0.000325	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by FGFR in disease—AKT1—thymus cancer	3.27e-05	0.000323	CbGpPWpGaD
Nilotinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	3.27e-05	0.000323	CbGpPWpGaD
Nilotinib—PDGFRB—DAP12 interactions—AKT1—thymus cancer	3.27e-05	0.000323	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—KIT—thymus cancer	3.26e-05	0.000322	CbGpPWpGaD
Nilotinib—MAPK14—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	3.26e-05	0.000322	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—KIT—thymus cancer	3.25e-05	0.000321	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by EGFR—AKT1—thymus cancer	3.24e-05	0.00032	CbGpPWpGaD
Nilotinib—HCK—Disease—KIT—thymus cancer	3.23e-05	0.000319	CbGpPWpGaD
Nilotinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	3.22e-05	0.000318	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by EGFR in Cancer—AKT1—thymus cancer	3.21e-05	0.000318	CbGpPWpGaD
Nilotinib—LYN—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	3.2e-05	0.000317	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by PDGF—AKT1—thymus cancer	3.2e-05	0.000316	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—KIT—thymus cancer	3.2e-05	0.000316	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAML2—thymus cancer	3.19e-05	0.000315	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—KIT—thymus cancer	3.17e-05	0.000313	CbGpPWpGaD
Nilotinib—BLK—Immune System—KIT—thymus cancer	3.17e-05	0.000313	CbGpPWpGaD
Nilotinib—MAPK14—MAPK Signaling Pathway—AKT1—thymus cancer	3.17e-05	0.000313	CbGpPWpGaD
Nilotinib—FGR—Immune System—KIT—thymus cancer	3.16e-05	0.000312	CbGpPWpGaD
Nilotinib—LCK—Signaling by SCF-KIT—AKT1—thymus cancer	3.15e-05	0.000311	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—KIT—thymus cancer	3.13e-05	0.00031	CbGpPWpGaD
Nilotinib—LCK—Disease—MAML2—thymus cancer	3.12e-05	0.000308	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—KIT—thymus cancer	3.09e-05	0.000306	CbGpPWpGaD
Nilotinib—PDGFRB—Focal Adhesion—AKT1—thymus cancer	3.09e-05	0.000306	CbGpPWpGaD
Nilotinib—EPHA2—Developmental Biology—AKT1—thymus cancer	3.09e-05	0.000305	CbGpPWpGaD
Nilotinib—MAPK11—Metabolism of RNA—AKT1—thymus cancer	3.07e-05	0.000304	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD8A—thymus cancer	3.03e-05	0.000299	CbGpPWpGaD
Nilotinib—PDGFRB—B Cell Activation—AKT1—thymus cancer	3.03e-05	0.000299	CbGpPWpGaD
Nilotinib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thymus cancer	3.03e-05	0.000299	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAML2—thymus cancer	3.02e-05	0.000298	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling of activated FGFR—AKT1—thymus cancer	3.01e-05	0.000298	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	3e-05	0.000296	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—CD4—thymus cancer	2.99e-05	0.000295	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB4—AKT1—thymus cancer	2.97e-05	0.000293	CbGpPWpGaD
Nilotinib—LYN—B Cell Activation—AKT1—thymus cancer	2.97e-05	0.000293	CbGpPWpGaD
Nilotinib—MAPK11—Signaling by NGF—AKT1—thymus cancer	2.9e-05	0.000286	CbGpPWpGaD
Nilotinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	2.9e-05	0.000286	CbGpPWpGaD
Nilotinib—BRAF—Signaling by NGF—AKT1—thymus cancer	2.87e-05	0.000284	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CD4—thymus cancer	2.87e-05	0.000284	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD8A—thymus cancer	2.87e-05	0.000283	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	2.86e-05	0.000282	CbGpPWpGaD
Nilotinib—LCK—Downstream signal transduction—AKT1—thymus cancer	2.83e-05	0.00028	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—CD4—thymus cancer	2.83e-05	0.00028	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR—AKT1—thymus cancer	2.82e-05	0.000279	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB2—AKT1—thymus cancer	2.81e-05	0.000277	CbGpPWpGaD
Nilotinib—LCK—DAP12 signaling—AKT1—thymus cancer	2.79e-05	0.000276	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	2.75e-05	0.000272	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—TP53—thymus cancer	2.72e-05	0.000269	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAML2—thymus cancer	2.72e-05	0.000269	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CD4—thymus cancer	2.72e-05	0.000268	CbGpPWpGaD
Nilotinib—MAPK14—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	2.69e-05	0.000266	CbGpPWpGaD
Nilotinib—LYN—Platelet activation, signaling and aggregation—AKT1—thymus cancer	2.68e-05	0.000265	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—KIT—thymus cancer	2.67e-05	0.000264	CbGpPWpGaD
Nilotinib—HCK—Immune System—CD4—thymus cancer	2.67e-05	0.000264	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAML2—thymus cancer	2.66e-05	0.000263	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—AKT1—thymus cancer	2.63e-05	0.000259	CbGpPWpGaD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	2.63e-05	0.000259	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—AKT1—thymus cancer	2.63e-05	0.000259	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—AKT1—thymus cancer	2.61e-05	0.000258	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—TP53—thymus cancer	2.61e-05	0.000258	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR—AKT1—thymus cancer	2.6e-05	0.000257	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD8A—thymus cancer	2.58e-05	0.000255	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—AKT1—thymus cancer	2.58e-05	0.000255	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—AKT1—thymus cancer	2.57e-05	0.000254	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—KIT—thymus cancer	2.57e-05	0.000254	CbGpPWpGaD
Nilotinib—MAPK14—Metabolism of mRNA—AKT1—thymus cancer	2.56e-05	0.000253	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—IL2—thymus cancer	2.55e-05	0.000252	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—CD4—thymus cancer	2.55e-05	0.000252	CbGpPWpGaD
Nilotinib—MAPK14—Platelet activation, signaling and aggregation—AKT1—thymus cancer	2.54e-05	0.000251	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—IL2—thymus cancer	2.54e-05	0.000251	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD8A—thymus cancer	2.53e-05	0.00025	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—KIT—thymus cancer	2.52e-05	0.000249	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAML2—thymus cancer	2.52e-05	0.000249	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD8A—thymus cancer	2.52e-05	0.000249	CbGpPWpGaD
Nilotinib—CA3—Metabolism—AKT1—thymus cancer	2.52e-05	0.000249	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—CD4—thymus cancer	2.5e-05	0.000247	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—CD4—thymus cancer	2.48e-05	0.000245	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—AKT1—thymus cancer	2.47e-05	0.000244	CbGpPWpGaD
Nilotinib—HCK—Disease—CD4—thymus cancer	2.47e-05	0.000244	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL2—thymus cancer	2.46e-05	0.000243	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD4—thymus cancer	2.45e-05	0.000242	CbGpPWpGaD
Nilotinib—LCK—B Cell Activation—AKT1—thymus cancer	2.43e-05	0.00024	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD4—thymus cancer	2.42e-05	0.000239	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD4—thymus cancer	2.42e-05	0.000239	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—IL2—thymus cancer	2.42e-05	0.000239	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD4—thymus cancer	2.41e-05	0.000239	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD8A—thymus cancer	2.4e-05	0.000237	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD4—thymus cancer	2.4e-05	0.000237	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—CD4—thymus cancer	2.37e-05	0.000234	CbGpPWpGaD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	2.33e-05	0.00023	CbGpPWpGaD
Nilotinib—BRAF—Disease—KIT—thymus cancer	2.31e-05	0.000228	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—AKT1—thymus cancer	2.3e-05	0.000227	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—AKT1—thymus cancer	2.29e-05	0.000226	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—AKT1—thymus cancer	2.23e-05	0.00022	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL2—thymus cancer	2.23e-05	0.00022	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL2—thymus cancer	2.23e-05	0.00022	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL2—thymus cancer	2.22e-05	0.00022	CbGpPWpGaD
Nilotinib—LCK—Platelet activation, signaling and aggregation—AKT1—thymus cancer	2.2e-05	0.000217	CbGpPWpGaD
Nilotinib—MAPK14—Metabolism of RNA—AKT1—thymus cancer	2.19e-05	0.000217	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAML2—thymus cancer	2.18e-05	0.000216	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KIT—thymus cancer	2.15e-05	0.000213	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—IL2—thymus cancer	2.09e-05	0.000207	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—AKT1—thymus cancer	2.08e-05	0.000205	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD8A—thymus cancer	2.07e-05	0.000205	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—AKT1—thymus cancer	2.07e-05	0.000204	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—AKT1—thymus cancer	2.07e-05	0.000204	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KIT—thymus cancer	2.05e-05	0.000202	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CD4—thymus cancer	2.05e-05	0.000202	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—AKT1—thymus cancer	1.99e-05	0.000197	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KIT—thymus cancer	1.99e-05	0.000197	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD4—thymus cancer	1.96e-05	0.000194	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KIT—thymus cancer	1.95e-05	0.000192	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KIT—thymus cancer	1.94e-05	0.000192	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD4—thymus cancer	1.93e-05	0.000191	CbGpPWpGaD
Nilotinib—LYN—Immune System—KIT—thymus cancer	1.9e-05	0.000188	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KIT—thymus cancer	1.89e-05	0.000187	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—AKT1—thymus cancer	1.87e-05	0.000185	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KIT—thymus cancer	1.8e-05	0.000178	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KIT—thymus cancer	1.79e-05	0.000177	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—AKT1—thymus cancer	1.79e-05	0.000177	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL2—thymus cancer	1.78e-05	0.000175	CbGpPWpGaD
Nilotinib—BRAF—Disease—CD4—thymus cancer	1.77e-05	0.000174	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD4—thymus cancer	1.74e-05	0.000172	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—AKT1—thymus cancer	1.65e-05	0.000163	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD4—thymus cancer	1.65e-05	0.000163	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—thymus cancer	1.64e-05	0.000162	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KIT—thymus cancer	1.63e-05	0.000161	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—thymus cancer	1.63e-05	0.000161	CbGpPWpGaD
Nilotinib—CA14—Metabolism—AKT1—thymus cancer	1.62e-05	0.00016	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KIT—thymus cancer	1.62e-05	0.00016	CbGpPWpGaD
Nilotinib—KIT—Disease—CD4—thymus cancer	1.61e-05	0.000159	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL2—thymus cancer	1.6e-05	0.000158	CbGpPWpGaD
Nilotinib—CA6—Metabolism—AKT1—thymus cancer	1.58e-05	0.000156	CbGpPWpGaD
Nilotinib—LCK—Immune System—KIT—thymus cancer	1.56e-05	0.000154	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—thymus cancer	1.55e-05	0.000153	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	1.53e-05	0.000151	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—thymus cancer	1.52e-05	0.00015	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL2—thymus cancer	1.52e-05	0.00015	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—AKT1—thymus cancer	1.49e-05	0.000147	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—thymus cancer	1.48e-05	0.000147	CbGpPWpGaD
Nilotinib—CA7—Metabolism—AKT1—thymus cancer	1.48e-05	0.000146	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—thymus cancer	1.45e-05	0.000144	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—thymus cancer	1.45e-05	0.000143	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—thymus cancer	1.44e-05	0.000142	CbGpPWpGaD
Nilotinib—LCK—Disease—KIT—thymus cancer	1.44e-05	0.000142	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—AKT1—thymus cancer	1.43e-05	0.000141	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—AKT1—thymus cancer	1.41e-05	0.000139	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—AKT1—thymus cancer	1.41e-05	0.000139	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—AKT1—thymus cancer	1.4e-05	0.000139	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KIT—thymus cancer	1.39e-05	0.000138	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—AKT1—thymus cancer	1.38e-05	0.000137	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—thymus cancer	1.38e-05	0.000136	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—AKT1—thymus cancer	1.38e-05	0.000136	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—thymus cancer	1.37e-05	0.000135	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—thymus cancer	1.37e-05	0.000135	CbGpPWpGaD
Nilotinib—CA12—Metabolism—AKT1—thymus cancer	1.37e-05	0.000135	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—thymus cancer	1.37e-05	0.000135	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—AKT1—thymus cancer	1.36e-05	0.000134	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—thymus cancer	1.34e-05	0.000133	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—thymus cancer	1.34e-05	0.000132	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—AKT1—thymus cancer	1.34e-05	0.000132	CbGpPWpGaD
Nilotinib—HCK—Immune System—AKT1—thymus cancer	1.33e-05	0.000132	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—thymus cancer	1.33e-05	0.000132	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—AKT1—thymus cancer	1.31e-05	0.00013	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.29e-05	0.000128	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—AKT1—thymus cancer	1.27e-05	0.000126	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—thymus cancer	1.27e-05	0.000125	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KIT—thymus cancer	1.25e-05	0.000124	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—AKT1—thymus cancer	1.24e-05	0.000123	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—AKT1—thymus cancer	1.24e-05	0.000122	CbGpPWpGaD
Nilotinib—HCK—Disease—AKT1—thymus cancer	1.23e-05	0.000122	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KIT—thymus cancer	1.23e-05	0.000121	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—AKT1—thymus cancer	1.22e-05	0.000121	CbGpPWpGaD
Nilotinib—BLK—Immune System—AKT1—thymus cancer	1.21e-05	0.000119	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—AKT1—thymus cancer	1.21e-05	0.000119	CbGpPWpGaD
Nilotinib—FGR—Immune System—AKT1—thymus cancer	1.2e-05	0.000119	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—AKT1—thymus cancer	1.2e-05	0.000118	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—thymus cancer	1.19e-05	0.000118	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—AKT1—thymus cancer	1.18e-05	0.000117	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KIT—thymus cancer	1.16e-05	0.000115	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—thymus cancer	1.15e-05	0.000113	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—thymus cancer	1.14e-05	0.000112	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—AKT1—thymus cancer	1.13e-05	0.000112	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—thymus cancer	1.1e-05	0.000109	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—thymus cancer	1.1e-05	0.000108	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AKT1—thymus cancer	1.09e-05	0.000108	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AKT1—thymus cancer	1.05e-05	0.000103	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—thymus cancer	1.04e-05	0.000102	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—AKT1—thymus cancer	1.02e-05	0.000101	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KIT—thymus cancer	1.01e-05	9.95e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—thymus cancer	1e-05	9.9e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—thymus cancer	9.8e-06	9.68e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—thymus cancer	9.8e-06	9.68e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—thymus cancer	9.63e-06	9.52e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—thymus cancer	9.58e-06	9.46e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—thymus cancer	9.26e-06	9.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—thymus cancer	8.83e-06	8.72e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—thymus cancer	8.81e-06	8.7e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—thymus cancer	8.81e-06	8.7e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—thymus cancer	8.8e-06	8.69e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—thymus cancer	8.68e-06	8.58e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—thymus cancer	8.65e-06	8.54e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—thymus cancer	8.22e-06	8.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—thymus cancer	8.2e-06	8.1e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—thymus cancer	8.02e-06	7.92e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—thymus cancer	7.82e-06	7.72e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—thymus cancer	7.59e-06	7.5e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—thymus cancer	7.43e-06	7.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—thymus cancer	7.41e-06	7.32e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—thymus cancer	7.37e-06	7.29e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—thymus cancer	7.31e-06	7.22e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—thymus cancer	7.25e-06	7.16e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—thymus cancer	7.22e-06	7.13e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—thymus cancer	7.09e-06	7e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—thymus cancer	6.87e-06	6.79e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—thymus cancer	6.84e-06	6.76e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—thymus cancer	6.84e-06	6.75e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—thymus cancer	6.65e-06	6.57e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—thymus cancer	6.29e-06	6.22e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—thymus cancer	6.23e-06	6.15e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—thymus cancer	6.17e-06	6.09e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—thymus cancer	5.94e-06	5.87e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—thymus cancer	5.67e-06	5.6e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—thymus cancer	5.61e-06	5.55e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—thymus cancer	5.55e-06	5.49e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—thymus cancer	5.49e-06	5.42e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—thymus cancer	5.32e-06	5.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—thymus cancer	5.26e-06	5.2e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—thymus cancer	5.25e-06	5.18e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—thymus cancer	4.79e-06	4.73e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—thymus cancer	4.69e-06	4.63e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—thymus cancer	4.55e-06	4.5e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—thymus cancer	4.45e-06	4.4e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—thymus cancer	4.44e-06	4.39e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—thymus cancer	3.84e-06	3.8e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—thymus cancer	3.26e-06	3.22e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—thymus cancer	2.76e-06	2.73e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—thymus cancer	2.41e-06	2.38e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—thymus cancer	2.27e-06	2.24e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—thymus cancer	2.25e-06	2.22e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—thymus cancer	1.48e-06	1.47e-05	CbGpPWpGaD
